Evidence map›Paper›PMID 28843907›Full record

ReviewInternational immunopharmacology2017

CCL28 chemokine: An anchoring point bridging innate and adaptive immunity.

Teena Mohan, Lei Deng, Bao-Zhong Wang

Open access · greenAbstract readReview
In one paragraph

Review in International immunopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Teena MohanCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Ave, SE, Atlanta, GA 30303, USA.
Lei DengCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Ave, SE, Atlanta, GA 30303, USA.
Bao-Zhong WangCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Ave, SE, Atlanta, GA 30303, USA. Electronic address: bwang23@gsu.edu.
Georgia State University · US

Funding

Novel Influenza nano vaccines for broad cross protectionR01AI101047 · NIAID · GEORGIA STATE UNIVERSITY · PI WANG, BAOZHONG · 2012 to 2023
$6.1M
Novel vaccine to enhance breadth of influenza immunity by skin vaccinationR01AI116835 · NIAID · GEORGIA STATE UNIVERSITY · PI WANG, BAOZHONG · 2015 to 2018
$2.4M
NIAID NIH HHS R01 AI101047NIAID NIH HHS R01 AI116835
6 · The paper itself

Abstract

Chemokines are an extensive family of small proteins which, in conjunction with their receptors, guide the chemotactic activity of various immune cells throughout the body. CCL28, β- or CC chemokine, is involved in the host immunity at various epithelial and mucosal linings. The unique roles of CCL28 in several facets of immune responses have attracted considerable attention and may represent a promising approach to combat various infections. CCL28 displays a broad spectrum of antimicrobial activity against gram-negative and gram-positive bacteria, as well as fungi. Here, we will summarize various research findings regarding the antimicrobial activity of CCL28 and the relevant mechanisms behind it. We will explore how the structure of CCL28 is involved with this activity and how this function may have evolved. CCL28 displays strong homing capabilities for B and T cells at several mucosal and epithelial sites, and orchestrates the trafficking and functioning of lymphocytes. The chemotactic and immunomodulatory features of CCL28 through the interactions with its chemokine receptors, CCR10 and CCR3, will also be discussed in detail. Thus, in this review, we emphasize the dual properties of CCL28 and suggest its role as an anchoring point bridging the innate and adaptive immunity.

Indexed as

Adaptive ImmunityAnimalsAnti-Infective AgentsCell MovementChemokines, CCChemotaxisHumansImmunity, InnateLymphocytesMucous MembraneAnti-Infective AgentsCCL28 protein, humanChemokines, CCAdjuvantsAntimicrobial proteinsChemokinesInnate immunityMucosal responses

Identifiers

PMID28843907
PMCPMC5755716
OpenAlexW2753345042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.